SCHEMBL14829253

SCHEMBL14829253

COc1ccc(-c2cccnc2CC=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 1/20 0.49
SYK P43405 8/20 0.48
AURKB Q96GD4 2/20 0.48
INCENP Q9NQS7 2/20 0.48
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
ABL1 P00519 1/20 0.42
ABCB1 P08183 1/20 0.42
BCR P11274 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
AURKA O14965 1/20 0.40
CCNB2 O95067 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
RIPK1 Q13546 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28890684 0.85 CLK4 (0.56) CLK4SYKAURKBINCENPKDM4E
SCHEMBL30802510 0.80 TOP1 (0.39) SYKALDH1A1
SCHEMBL29157725 0.80 TOP1 (0.39) SYKALDH1A1
SCHEMBL1515689 0.80 ABL1 (0.50) SYKAURKBINCENPKDM4EABL1
SCHEMBL14484609 0.78 CLK4 (0.51) CLK4SYKAURKBINCENPKDM4E
SCHEMBL4095298 0.74 CLK4 (0.58) CLK4SYKAURKBINCENPKDM4E
SCHEMBL7113110 0.74 KDM4E (0.67) CLK4SYKAURKBINCENPKDM4E
SCHEMBL13063994 0.74 NFE2L2 (0.42) RAB9ANPC1AURKA
SCHEMBL29796666 0.74 NFE2L2 (0.42) RAB9ANPC1AURKA
SCHEMBL20840603 0.73 NPC1 (0.51) CLK4KDM4EALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760854-A1 IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER Endo Pharmaceuticals Inc. (US) 2014-08-06 EP disclosed
WO-2013049565-A1 IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER ENDO PHARMACEUTICALS INC. (US) 2013-04-04 WO disclosed